vs
Orchid Island Capital, Inc.（ORC）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是Orchid Island Capital, Inc.的1.8倍（$69.8M vs $38.5M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 268.7%，领先115.3%），Orchid Island Capital, Inc.同比增速更快（372.6% vs 21.2%），过去两年Orchid Island Capital, Inc.的营收复合增速更高（301.6% vs 53.7%）
Orchid Island Capital是一家总部设在美国的专业金融企业，以房地产投资信托的形式开展运营，主要投资机构类及非机构类住宅抵押贷款支持证券，深耕美国固定收益市场，致力于为投资者创造稳定的经风险调整后的长期回报。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
ORC vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.8倍
$38.5M
营收增速更快
ORC
高出351.4%
21.2%
净利率更高
RIGL
高出115.3%
268.7%
两年增速更快
ORC
近两年复合增速
53.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $38.5M | $69.8M |
| 净利润 | $103.4M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | — | 33.2% |
| 净利率 | 268.7% | 384.0% |
| 营收同比 | 372.6% | 21.2% |
| 净利润同比 | 1764.9% | 1769.2% |
| 每股收益（稀释后） | — | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ORCRIGL
| Q4 25 | $38.5M | $69.8M | ||
| Q3 25 | $26.9M | $69.5M | ||
| Q2 25 | $23.2M | $101.7M | ||
| Q1 25 | $19.7M | $53.3M | ||
| Q4 24 | — | $57.6M | ||
| Q3 24 | $340.0K | $55.3M | ||
| Q2 24 | $-697.0K | $36.8M | ||
| Q1 24 | $-2.5M | $29.5M |
净利润ORCRIGL
| Q4 25 | $103.4M | $268.1M | ||
| Q3 25 | $72.1M | $27.9M | ||
| Q2 25 | $-33.6M | $59.6M | ||
| Q1 25 | $17.1M | $11.4M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | $17.3M | $12.4M | ||
| Q2 24 | $-5.0M | $-1.0M | ||
| Q1 24 | $19.8M | $-8.2M |
毛利率ORCRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率ORCRIGL
| Q4 25 | — | 33.2% | ||
| Q3 25 | — | 40.9% | ||
| Q2 25 | — | 60.1% | ||
| Q1 25 | — | 23.9% | ||
| Q4 24 | — | 28.9% | ||
| Q3 24 | — | 25.4% | ||
| Q2 24 | — | 1.2% | ||
| Q1 24 | — | -23.6% |
净利率ORCRIGL
| Q4 25 | 268.7% | 384.0% | ||
| Q3 25 | 267.8% | 40.2% | ||
| Q2 25 | -145.0% | 58.6% | ||
| Q1 25 | 86.9% | 21.5% | ||
| Q4 24 | — | 24.9% | ||
| Q3 24 | 5094.1% | 22.5% | ||
| Q2 24 | 714.3% | -2.8% | ||
| Q1 24 | -794.2% | -27.9% |
每股收益（稀释后）ORCRIGL
| Q4 25 | — | $14.11 | ||
| Q3 25 | — | $1.46 | ||
| Q2 25 | — | $3.28 | ||
| Q1 25 | — | $0.63 | ||
| Q4 24 | — | $0.82 | ||
| Q3 24 | — | $0.70 | ||
| Q2 24 | — | $-0.06 | ||
| Q1 24 | — | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $665.9M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $1.4B | $391.5M |
| 总资产 | $11.7B | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资ORCRIGL
| Q4 25 | $665.9M | $155.0M | ||
| Q3 25 | $583.9M | $137.1M | ||
| Q2 25 | $440.8M | $108.4M | ||
| Q1 25 | $396.4M | $77.1M | ||
| Q4 24 | — | $77.3M | ||
| Q3 24 | $322.1M | $61.1M | ||
| Q2 24 | $241.0M | $49.1M | ||
| Q1 24 | $190.4M | $49.5M |
总债务ORCRIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益ORCRIGL
| Q4 25 | $1.4B | $391.5M | ||
| Q3 25 | $1.1B | $117.6M | ||
| Q2 25 | $912.0M | $81.9M | ||
| Q1 25 | $855.9M | $18.6M | ||
| Q4 24 | — | $3.3M | ||
| Q3 24 | $656.0M | $-14.6M | ||
| Q2 24 | $555.9M | $-29.9M | ||
| Q1 24 | $481.6M | $-31.7M |
总资产ORCRIGL
| Q4 25 | $11.7B | $513.6M | ||
| Q3 25 | $9.1B | $242.5M | ||
| Q2 25 | $7.6B | $206.7M | ||
| Q1 25 | $7.3B | $176.0M | ||
| Q4 24 | — | $164.0M | ||
| Q3 24 | $5.9B | $139.4M | ||
| Q2 24 | $4.9B | $128.4M | ||
| Q1 24 | $4.2B | $126.5M |
负债/权益比ORCRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $120.4M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 1.16× | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ORCRIGL
| Q4 25 | $120.4M | $22.0M | ||
| Q3 25 | $28.0M | $24.0M | ||
| Q2 25 | $18.4M | $30.5M | ||
| Q1 25 | $25.8M | $-893.0K | ||
| Q4 24 | — | $14.5M | ||
| Q3 24 | $-14.8M | $21.7M | ||
| Q2 24 | $19.3M | $302.0K | ||
| Q1 24 | $45.0M | $-5.0M |
现金转化率ORCRIGL
| Q4 25 | 1.16× | 0.08× | ||
| Q3 25 | 0.39× | 0.86× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | 1.51× | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | -0.86× | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
